Inflammatory diseases and bone fragility

K. Briot, P. Geusens, I. Bultink, W. F. Lems, C. Roux

Research output: Contribution to journalReview articleAcademicpeer-review

Abstract

Systemic osteoporosis and increased fracture rates have been described in chronic inflammatory diseases such as rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, inflammatory bowel diseases, and chronic obstructive pulmonary disease. Most of these patients receive glucocorticoids, which have their own deleterious effects on bone. However, the other main determinant of bone fragility is the inflammation itself, as shown by the interactions between the inflammatory mediators, the actors of the immune system, and the bone remodelling. The inflammatory disease activity is thus on top of the other well-known osteoporotic risk factors in these patients. Optimal control of inflammation is part of the prevention of osteoporosis, and potent anti-inflammatory drugs have positive effects on surrogate markers of bone fragility. More data are needed to assess the anti-fracture efficacy of a tight control of inflammation in patients with a chronic inflammatory disorder. This review aimed at presenting different clinical aspects of inflammatory diseases which illustrate the relationships between inflammation and bone fragility.

Original languageEnglish
Pages (from-to)3301-3314
Number of pages14
JournalOsteoporosis International
Volume28
Issue number12
DOIs
Publication statusPublished - 1 Dec 2017

Cite this

Briot, K. ; Geusens, P. ; Bultink, I. ; Lems, W. F. ; Roux, C. / Inflammatory diseases and bone fragility. In: Osteoporosis International. 2017 ; Vol. 28, No. 12. pp. 3301-3314.
@article{4835262551e44cd4b89983a31fecaf6a,
title = "Inflammatory diseases and bone fragility",
abstract = "Systemic osteoporosis and increased fracture rates have been described in chronic inflammatory diseases such as rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, inflammatory bowel diseases, and chronic obstructive pulmonary disease. Most of these patients receive glucocorticoids, which have their own deleterious effects on bone. However, the other main determinant of bone fragility is the inflammation itself, as shown by the interactions between the inflammatory mediators, the actors of the immune system, and the bone remodelling. The inflammatory disease activity is thus on top of the other well-known osteoporotic risk factors in these patients. Optimal control of inflammation is part of the prevention of osteoporosis, and potent anti-inflammatory drugs have positive effects on surrogate markers of bone fragility. More data are needed to assess the anti-fracture efficacy of a tight control of inflammation in patients with a chronic inflammatory disorder. This review aimed at presenting different clinical aspects of inflammatory diseases which illustrate the relationships between inflammation and bone fragility.",
keywords = "Bone densitometry, Fracture, Inflammation, Osteoporosis",
author = "K. Briot and P. Geusens and I. Bultink and Lems, {W. F.} and C. Roux",
year = "2017",
month = "12",
day = "1",
doi = "10.1007/s00198-017-4189-7",
language = "English",
volume = "28",
pages = "3301--3314",
journal = "Osteoporosis International",
issn = "0937-941X",
publisher = "Springer London",
number = "12",

}

Inflammatory diseases and bone fragility. / Briot, K.; Geusens, P.; Bultink, I.; Lems, W. F.; Roux, C.

In: Osteoporosis International, Vol. 28, No. 12, 01.12.2017, p. 3301-3314.

Research output: Contribution to journalReview articleAcademicpeer-review

TY - JOUR

T1 - Inflammatory diseases and bone fragility

AU - Briot, K.

AU - Geusens, P.

AU - Bultink, I.

AU - Lems, W. F.

AU - Roux, C.

PY - 2017/12/1

Y1 - 2017/12/1

N2 - Systemic osteoporosis and increased fracture rates have been described in chronic inflammatory diseases such as rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, inflammatory bowel diseases, and chronic obstructive pulmonary disease. Most of these patients receive glucocorticoids, which have their own deleterious effects on bone. However, the other main determinant of bone fragility is the inflammation itself, as shown by the interactions between the inflammatory mediators, the actors of the immune system, and the bone remodelling. The inflammatory disease activity is thus on top of the other well-known osteoporotic risk factors in these patients. Optimal control of inflammation is part of the prevention of osteoporosis, and potent anti-inflammatory drugs have positive effects on surrogate markers of bone fragility. More data are needed to assess the anti-fracture efficacy of a tight control of inflammation in patients with a chronic inflammatory disorder. This review aimed at presenting different clinical aspects of inflammatory diseases which illustrate the relationships between inflammation and bone fragility.

AB - Systemic osteoporosis and increased fracture rates have been described in chronic inflammatory diseases such as rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, inflammatory bowel diseases, and chronic obstructive pulmonary disease. Most of these patients receive glucocorticoids, which have their own deleterious effects on bone. However, the other main determinant of bone fragility is the inflammation itself, as shown by the interactions between the inflammatory mediators, the actors of the immune system, and the bone remodelling. The inflammatory disease activity is thus on top of the other well-known osteoporotic risk factors in these patients. Optimal control of inflammation is part of the prevention of osteoporosis, and potent anti-inflammatory drugs have positive effects on surrogate markers of bone fragility. More data are needed to assess the anti-fracture efficacy of a tight control of inflammation in patients with a chronic inflammatory disorder. This review aimed at presenting different clinical aspects of inflammatory diseases which illustrate the relationships between inflammation and bone fragility.

KW - Bone densitometry

KW - Fracture

KW - Inflammation

KW - Osteoporosis

UR - http://www.scopus.com/inward/record.url?scp=85029533643&partnerID=8YFLogxK

U2 - 10.1007/s00198-017-4189-7

DO - 10.1007/s00198-017-4189-7

M3 - Review article

VL - 28

SP - 3301

EP - 3314

JO - Osteoporosis International

JF - Osteoporosis International

SN - 0937-941X

IS - 12

ER -